carfilzomib

Carfilzomib synergized with BCL2 family protein inhibitors (navitoclax or AZD5991), suggesting that drug combinations could be used to reduce the dose of each drug to minimize toxicity. Notably, thymic carcinomas differed from squamous cell carcinomas in other organs by higher levels of β5i (PSMB8) and constitutive proteasome β5 (PSMB5). We hypothesize that TC (and probably many TH) are uniquely suited for treatment with proteasome inhibitors alone or in combination with selective BH3 mimetics.

P=N/A, N=359, Completed, iOMEDICO AG | Active, not recruiting --> Completed

P3, N=614, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting

P2, N=75, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Sep 2026 --> May 2025

P2, N=28, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended

HLA-A2:WT1 TCR-like antibody can effectively reflect the APM function. Some of the anti-tumor drugs can affect the APM function and immunogenicity of tumor cells.

We tested carfilzomib's efficacy against gastric cancer by subcutaneously implanting nude mice with human gastric epithelial-derived tumors and treating them with carfilzomib, either alone or in combination with 5-fluorouracil (5-FU), a standard-of-care drug. These results strongly suggest that PSMB8 is a suitable candidate for targeted therapy. Moreover, with carfilzomib having robust anti-tumor activity, it has potential as a treatment option for cancers where high levels of PSMB8 are associated with poor overall survival.

P2, N=200, Not yet recruiting, GlaxoSmithKline

Combined treatment with carfilzomib and doxorubicin failed to induce synergistic cell death in three MM cell lines (LP-1, RPMI-8266, and NCI-H929) lacking aggresome-forming capability, which exhibited higher sensitivity to carfilzomib than U266B1 cells. In conclusion, our findings suggest that doxorubicin enhances carfilzomib-induced cell death by inhibiting aggresome formation and that the combined treatment with carfilzomib and doxorubicin may be an effective strategy to target MM cells with aggresome-forming activity.

P1, N=52, Completed, University of Chicago | Recruiting --> Completed | N=100 --> 52 | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Jul 2026 --> Oct 2025

P=N/A, N=46, Recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine

P3, N=915, Not yet recruiting, Regeneron Pharmaceuticals